Lifestyle Factors Associated With Liver Cancer Risk
The risk of developing liver cancer may be increased by excessive body fat and decreased by coffee consumption.
Stephen Hursting, PhD, MPH
The risk of developing liver cancer may be increased by excessive body fat and decreased by coffee consumption, according to an ongoing systematic review conducted in collaboration with the American Institute of Cancer Research.
The large international study analyzed data from 34 studies involving 8.2 million individuals, with over 24,500 liver cancer diagnoses. The World Cancer Research Fund International’s Continuous Update Project (CUP) completed the study.
In addition to new connections between coffee intake and weight, the report strengthened the association between alcohol and liver cancer. Taken together, the researchers estimated that maintaining a healthy weight and avoiding alcohol consumption could prevent 30% of new liver cancer cases (nearly 10,700 in 2015).
"This is the first time there's been such a clear signal from a rigorous systematic review on the links between obesity increasing risk of liver cancer and coffee decreasing risk," Stephen Hursting, PhD, MPH, researcher at the University of North Carolina Chapel Hill and one of the CUP expert panelists, said in a statement.
The reduction in risk seen with coffee consumption adds to a 2013 report connecting coffee with endometrial cancer prevention. Further research is examining whether coffee contains anti-cancer components. "[Coffee] may act on liver enzymes that eliminate carcinogens, for example," Hursting speculated.
Obesity has been associated with a variety of cancer types, including breast cancer. Research suggests that inflammation caused by obesity could be a leading cause for the increase in cancer. In general, a high fat diet and a BMI over 30 leads to increased proinflammatory mediators.
"The evidence on obesity and cancer is only getting stronger," said Hursting. "We're looking at a tsunami of obesity-related cancer coming. People really need to be aware of this issue and we need more research on weight loss strategies and understanding the mechanisms so that we can break this connection."
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
January 16th 2025Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated treatment, others remain resistant, highlighting the need for targeted approaches to improve outcomes.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
